Last updated on August 2019

An Investigational Immuno-therapy Study of Nivolumab or Placebo in Participants With Resected Esophageal or Gastroesophageal Junction Cancer


Brief description of study

The primary purpose of this study is to determine whether Nivolumab will improve disease-free survival compared with placebo.

Clinical Study Identifier: NCT02743494

Find a site near you

Start Over

Local Institution

Ramat-gan, Israel
2.78miles
  Connect »

Local Institution

Petach Tikva, Israel
6.21miles
  Connect »